Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study.
OBJECTIVE
To assess the efficacy of alprazolam in the treatment of two groups of patients diagnosed with late luteal phase dysphoric disorder (LLPDD). The first group met only the diagnostic criteria for LLPDD. The second group experienced LLPDD and mild symptoms of anxiety and depression during the follicular phase.


METHODS
A double-blind, placebo-controlled crossover design was used. Patients were treated with alprazolam and placebo for 3 months each and completed daily measures of anxiety, tension, depression, irritability, and feelings of being out of control.


RESULTS
The response to alprazolam differed significantly by group. For the first group, alprazolam (0.25 mg three times a day) relieved the severity of tension (P = .001), irritability (P = .005), anxiety (P = .008), and feelings of being out of control (P = .012) more than placebo. Few side effects were reported; the incidence (P = .001) and severity (P = .001) of side effects were dose-related. Alprazolam and placebo did not differ for the second group, and the incidence and severity of side effects were unrelated to dose.


CONCLUSIONS
Alprazolam benefits women diagnosed solely with LLPDD. It is not recommended for patients who experience LLPDD as well as symptoms of mild anxiety or depression during the follicular phase.
Berger
C P
CP
Department of Obstetrics and Gynaecology, Montreal General Hospital, Quebec, Canada.
Presser
B
B
D000328:Adult; D000525:Alprazolam / Q000627:therapeutic use*; D000704:Analysis of Variance; D004311:Double-Blind Method; D005260:Female; D005498:Follicular Phase / Q000523:psychology; D006801:Humans; D008183:Luteal Phase / Q000523:psychology; D011293:Premenstrual Syndrome / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology
D000525:Alprazolam